Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Investor's Business Daily on MSN1d
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss DrugNovo Nordisk stock tumbled Friday — pulling Corbus Pharmaceuticals into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.Please watch the video at ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...
It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback